Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5957)
All Articles published online
|
Publishing Process of This Article
|
Oct 19, 2021 (publication date) through Nov 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Psychiatry
ISSN
2220-3206
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Kurimoto N, Inagaki T, Aoki T, Kadotani H, Kurimoto F, Kuriyama K, Yamada N, Ozeki Y. Factors causing a relapse of major depressive disorders following successful electroconvulsive therapy: A retrospective cohort study. World J Psychiatr 2021; 11(10): 841-853 [PMID: 34733646 DOI: 10.5498/wjp.v11.i10.841] |
|---|---|
| URL: | https://www.wjgnet.com/2220-3206/full/v11/i10/841.htm |
| Number | Citing Articles |
| 1 |
Octavian Vasiliu. Efficacy, Tolerability, and Safety of Toludesvenlafaxine for the Treatment of Major Depressive Disorder—A Narrative Review. Pharmaceuticals 2023; 16(3): 411 doi: 10.3390/ph16030411
|
| 2 |
Gopalkumar Rakesh, Patrick Cordero, Rebika Khanal, Seth S. Himelhoch, Craig R. Rush. Optimally combining transcranial magnetic stimulation with antidepressants in major depressive disorder: A systematic review and Meta-analysis. Journal of Affective Disorders 2024; 358: 432 doi: 10.1016/j.jad.2024.05.037
|
| 3 |
Akise Umakoshi, Masahiro Takeshima, Yu Itoh, Mari Yamamoto, Nana Shibata, Masaya Ogasawara, Naoko Ayabe, Kazuo Mishima. Relationship among psychotic features, benzodiazepine receptor agonists, and rehospitalization in patients with electroconvulsive therapy‐responsive major depressive disorder: A retrospective 2‐year observational study. Neuropsychopharmacology Reports 2022; 42(4): 449 doi: 10.1002/npr2.12282
|